New hope for aggressive brain cancer as scientists test Dual-Attack therapy

This early-stage study is testing the safety and initial effectiveness of combining two drugs, acalabrutinib and durvalumab, for adults with primary central nervous system (CNS) lymphoma, a rare and aggressive cancer of the brain or spine. The trial is for patients whose cancer has returned after prior treatment or who cannot receive standard high-dose chemotherapy. Researchers aim to see if this two-drug approach can better control the disease with manageable side effects.